Ranbaxy Claims Greatest Indian Market Share, Ahead of Cipla, GSK
This article was originally published in PharmAsia News
Ranbaxy Laboratories beat out Cipla as India's drug maker with the highest share of the domestic market in July. Ranbaxy claimed a 5.1 percent market share during the month, while Cipla recorded a 4.89 percent share. Ranbaxy's sales for the month increased by 13.4 percent compared with Cipla's 9.7 percent. The audit by ORG-IMS gave U.K. drug maker GlaxoSmithKline the third largest market share, followed by Indian makers Piramal Healthcare and Zydus Cadila. (Click here for more
You may also be interested in...
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.